A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma

Biochemical and Biophysical Research Communications
Xing LiuYukinari Kato

Abstract

Isocitrate dehydrogenase 2 (IDH2) mutations have been reported in gliomas, osteosarcomas, cartilaginous tumors, giant cell tumors of bone, and acute myeloid leukemias. Although IDH2 catalyzes the oxidative carboxylation of isocitrate to α-ketoglutarate (α-KG) in mitochondria, mutated IDH2 proteins possess the ability to change α-KG into the oncometabolite R(-)-2-hydroxyglutarate (2-HG). To date, several monoclonal antibodies (mAbs) specific for IDH2 mutations have been established, such as KMab-1 against IDH2-R172K, MMab-1 against IDH2-R172M, and WMab-1 against IDH2-R172W. Although a multi-specific mAb MsMab-1 reacted with IDH2-R172G and IDH2-R172S, a mono-specific mAb against IDH2-R172S has not been established. In this study, we established a novel mAb SMab-2, which recognizes IDH2-R172S but not with wild type IDH2 in ELISA. Although SMab-2 reacted with both IDH1-R132S and IDH2-R172S expressed in Escherichia coli, it reacted with only IDH2-R172S expressed in U-2 OS osteosarcoma cells. Furthermore, SMab-2 recognized endogenous IDH2-R172S protein expressed in SW1353 chondrosarcoma cells in Western blot and immunocytochemical analyses. SMab-2 is expected to be useful for diagnosis of IDH2-R172S-bearing tumors.

References

Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Jan 29, 2010·The New England Journal of Medicine·Anthony Green, Philip Beer
Mar 1, 2011·Biochemical and Biophysical Research Communications·Mika Kato KanekoYukinari Kato
Nov 1, 2011·Analytical Chemistry·Benjamin J HindsonBill W Colston
Nov 8, 2011·Nature Genetics·M Fernanda AmaryAdrienne M Flanagan
Feb 2, 2013·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Brendan PangMarina N Nikiforova
Feb 5, 2013·Biochemical and Biophysical Research Communications·Mika Kato KanekoYukinari Kato
Mar 26, 2013·Biochemical and Biophysical Research Communications·Yukinari Kato, Mika Kato Kaneko
Jun 21, 2013·The Tohoku Journal of Experimental Medicine·Mika Kato KanekoYukinari Kato
Dec 18, 2013·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Satoshi OgasawaraYukinari Kato
Jun 6, 2014·Cancer Science·Mika Kato KanekoYukinari Kato
Jul 11, 2014·Brain Tumor Pathology·Hideyuki AritaKoichi Ichimura

❮ Previous
Next ❯

Citations

Oct 28, 2016·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Satoshi OgasawaraYukinari Kato
Mar 25, 2017·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Yuki FujiiYukinari Kato

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Related Papers

Biochemical and Biophysical Research Communications
Yukinari KatoMika Kato Kaneko
Biochemical and Biophysical Research Communications
Yukinari Kato, Mika Kato Kaneko
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
Satoshi OgasawaraYukinari Kato
© 2022 Meta ULC. All rights reserved